Product Description
An extended-release (ER) microparticle formulation of toll-like receptor type 7 and 8 (TLR 7/8) agonist, with potential immunostimulating and antitumor activities. Upon administration, TLR7/8 agonist BM201 targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr7-8-agonist-bm201)
Mechanisms of Action: TLR7 Agonist, TLR8 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Suzhou Baimai Biopharmaceutical Co., Ltd./Guangdong Xinghao Pharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20223162 |
CTR20223162 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
67% |
2025-08-17 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|